RedHill Biopharma Advances Gastrointestinal Health with Innovative Therapies and Strategic Partnerships
- RedHill Biopharma develops innovative therapies for gastrointestinal diseases, infectious diseases, and oncology.
- The partnership with Cumberland Pharmaceuticals enhances RedHill’s portfolio and addresses gastrointestinal health challenges.
- RedHill is advancing various treatment options, including opaganib and RHB-102, to meet unmet medical needs.
Innovative Solutions in Gastrointestinal Health: RedHill Biopharma’s Strategic Advances
RedHill Biopharma Ltd., a biopharmaceutical company based in Tel Aviv and Raleigh, remains dedicated to developing innovative therapies for gastrointestinal diseases, infectious diseases, and oncology. Recently, the company has successfully regained compliance with Nasdaq's stockholders' equity requirement as of November 26, 2025. This achievement is attributed to the strategic initiatives RedHill has undertaken, particularly its partnership with Cumberland Pharmaceuticals for the FDA-approved gastrointestinal drug, Talicia®, which effectively treats Helicobacter pylori infections in adults. This partnership not only enhances RedHill’s portfolio but also signifies its commitment to addressing pressing health challenges.
A major focus of RedHill’s pipeline includes opaganib (ABC294640), a first-in-class sphingosine kinase-2 inhibitor that targets various conditions, including gastrointestinal acute radiation syndrome and COVID-19. The company is also advancing RHB-204, a next-generation formulation aimed at treating Crohn's disease, alongside RHB-102, which has shown promising results in clinical trials for acute gastroenteritis, Irritable Bowel Syndrome-Diarrhea (IBS-D), and chemotherapy-induced nausea. The collaboration with Hyloris Pharma for the global development of RHB-102 outside North America demonstrates RedHill’s strategy of leveraging partnerships to enhance its market reach and therapeutic impact.
In addition to these promising therapies, RedHill is also developing RHB-107 (upamostat), a host-directed serine protease inhibitor aimed at treating non-hospitalized symptomatic COVID-19 and other gastrointestinal diseases. This diverse array of treatments underscores RedHill’s commitment to addressing unmet medical needs in the healthcare sector. By focusing on innovative solutions and strategic partnerships, RedHill Biopharma positions itself as a key player in advancing therapeutic options for patients facing significant health challenges. More details about their initiatives can be found on their website and social media platforms.
